ReviewAnnals of medicine and surgery (2012)2026
"Microbial metabolites in cardioprotection: an immune-engineered framework for heart failure and post-ischemic remodeling: a narrative review".
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gut-heart axis is a new therapeutic target for cardiovascular diseases, which continue to be the leading cause of death worldwide. Metabolites originating from microorganisms have demonstrated significant impacts on inflammation, remodeling, and heart function. Objective: By assessing molecular pathways, therapeutic options, and translational barriers, this narrative review seeks to objectively examine the cardioprotective potential of gut microbial metabolites. Methods: We reviewed and summarized the most recent research on the impact of microbial metabolites, both beneficial and detrimental, on endothelium repair, fibrosis, immunometabolism, and cardiac bioenergetics. A systematic search was conducted using the phrases "gut-heart axis," "microbial metabolites," and "cardiovascular protection" in PubMed, Scopus, and Web of Science for the years 2018-2024. Preclinical and clinical research that met the eligibility requirements were vetted and narratively synthesized. Results: By modulating Nrf2, HDAC, and TGF-β/Smad, protective metabolites such as short-chain fatty acids, urolithins, and indoles have anti-inflammatory, anti-fibrotic, and mitochondrial-enhancing properties. On the other hand, oxidative stress and fibrosis are made worse by trimethylamine N-oxide and hydrogen sulfide. Postbiotic formulations, innovative delivery systems, and synthetic biology provide promising approaches for focused intervention. However, there are substantial translational obstacles due to pharmacokinetic, regulatory, and microbiota heterogeneity. Conclusion: Microbial metabolites produced in the gut are a promising and revolutionary class of cardioprotectants. Future cardiovascular treatments may be redefined by precision-targeted gut-heart axis modulation, although clinical validation and regulatory standardization are still crucial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.